Claus F Vogelmeier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7084336/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	5.6	2,393
2	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	6.7	1,223
3	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	6.7	746
4	Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. New England Journal of Medicine, 2016, 374, 2222-2234.	27.0	688
5	Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. New England Journal of Medicine, 2011, 364, 1093-1103.	27.0	603
6	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 24-36.	5.6	417
7	Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respiratory Medicine,the, 2016, 4, 390-398.	10.7	349
8	European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α ₁ -antitrypsin deficiency. European Respiratory Journal, 2017, 50, 1700610.	6.7	244
9	Exacerbations of COPD. European Respiratory Review, 2018, 27, 170103.	7.1	189
10	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	27.0	180
11	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
12	Precision medicine in airway diseases: moving to clinical practice. European Respiratory Journal, 2017, 50, 1701655.	6.7	151
13	A review of national guidelines for management of COPD in Europe. European Respiratory Journal, 2016, 47, 625-637.	6.7	145
14	Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1189-1197.	5.6	139
15	Goals of COPD treatment: Focus on symptoms and exacerbations. Respiratory Medicine, 2020, 166, 105938.	2.9	135
16	Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Research, 2021, 7, 00108-2021.	2.6	133
17	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258.	5.6	121
18	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respiratory Medicine, 2016, 114, 27-37.	2.9	113

#	Article	IF	CITATIONS
19	Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respiratory Research, 2010, 11, 79.	3.6	107
20	Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1219-1221.	5.6	100
21	SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries. Advances in Therapy, 2020, 37, 1124-1135.	2.9	84
22	Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulmonary Medicine, 2016, 16, 70.	2.0	81
23	Efficacy and safety of aclidinium/formoterol <i>versus</i> salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal, 2016, 48, 1030-1039.	6.7	81
24	Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences–Comorbidities Network Study. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 189-197.	5.6	81
25	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory Research, 2019, 20, 238.	3.6	81
26	Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2255-2261.	3.8	76
27	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	5.6	72
28	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. European Respiratory Journal, 2017, 50, 1700671.	6.7	69
29	COPD 2020: changes and challenges. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L879-L883.	2.9	66
30	Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respiratory Research, 2013, 14, 116.	3.6	65
31	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	6.7	64
32	The â€~real-life' COPD patient in Germany: The DACCORD study. Respiratory Medicine, 2016, 111, 64-71.	2.9	58
33	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 17-24.	5.6	57
34	Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease. PLoS ONE, 2015, 10, e0132227.	2.5	55
35	<p>Personalized medicine for patients with COPD: where are we?</p> . International Journal of COPD, 2019, Volume 14, 1465-1484.	2.3	55
36	Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. European Respiratory Journal, 2019, 54, 1900673.	6.7	55

#	Article	IF	CITATIONS
37	Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research, 2017, 18, 140.	3.6	52
38	Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention. Respiratory Medicine, 2016, 111, 1-7.	2.9	50
39	"Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. International Journal of COPD, 2017, Volume 12, 487-494.	2.3	47
40	The revised GOLD 2017 COPD categorization in relation to comorbidities. Respiratory Medicine, 2018, 134, 79-85.	2.9	45
41	Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respiratory Medicine,the, 2014, 2, 44-53.	10.7	44
42	Perception of symptoms and quality of life – comparison of patients' and physicians' views in the COPD MIRROR study. International Journal of COPD, 2017, Volume 12, 2189-2196.	2.3	43
43	It is time for the world to take COPD seriously: a statement from the GOLD board of directors. European Respiratory Journal, 2019, 54, 1900914.	6.7	43
44	The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. International Journal of COPD, 2017, Volume 12, 1325-1337.	2.3	40
45	Proviral MicroRNAs Detected in Extracellular Vesicles From Bronchoalveolar Lavage Fluid of Patients With Influenza Virus–Induced Acute Respiratory Distress Syndrome. Journal of Infectious Diseases, 2019, 219, 540-543.	4.0	40
46	Comorbid Influences on Generic Health-Related Quality of Life in COPD: A Systematic Review. PLoS ONE, 2015, 10, e0132670.	2.5	40
47	Excess Costs of Comorbidities in Chronic Obstructive Pulmonary Disease: A Systematic Review. PLoS ONE, 2015, 10, e0123292.	2.5	39
48	New concepts in asthma: clinical phenotypes and pathophysiological mechanisms. Drug Discovery Today, 2017, 22, 388-396.	6.4	39
49	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS ONE, 2017, 12, e0177501.	2.5	37
50	Wall stress determines systolic and diastolic function — Characteristics of heart failure. International Journal of Cardiology, 2016, 202, 685-693.	1.7	35
51	Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respiratory Medicine, 2018, 137, 14-22.	2.9	35
52	Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respiratory Research, 2018, 19, 110.	3.6	35
53	<p>Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort</p> . International Journal of COPD, 2019, Volume 14, 2163-2172.	2.3	35
54	Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respiratory Research, 2019, 20, 178.	3.6	34

#	Article	IF	CITATIONS
55	A two-year evaluation of the â€~real life' impact of COPD on patients in Germany: The DACCORD observational study. Respiratory Medicine, 2017, 124, 57-64.	2.9	33
56	Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. Genomics, Proteomics and Bioinformatics, 2018, 16, 162-171.	6.9	33
57	Consequences of chronic kidney disease in chronic obstructive pulmonary disease. Respiratory Research, 2019, 20, 151.	3.6	33
58	Prevalence and Characteristics of Asthma–Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. Annals of the American Thoracic Society, 2019, 16, 1143-1150.	3.2	32
59	Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine, 2017, 122, 58-66.	2.9	30
60	One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 484-493.	1.6	29
61	A year in the life of German patients with COPD: the DACCORD observational study. International Journal of COPD, 2016, Volume 11, 1639-1646.	2.3	28
62	Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respiratory Research, 2018, 19, 251.	3.6	28
63	GOLD 2017 treatment pathways in â€ [~] real life': An analysis of the DACCORD observational study. Respiratory Medicine, 2017, 131, 77-84.	2.9	27
64	Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respiratory Research, 2017, 18, 171.	3.6	27
65	Left ventricular volume and wall stress are linked to lung function impairment in COPD. International Journal of Cardiology, 2018, 261, 172-178.	1.7	27
66	The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study. Journal of Epidemiology, 2019, 29, 315-324.	2.4	27
67	Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management. Advances in Therapy, 2017, 34, 281-299.	2.9	26
68	Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients. Cells, 2019, 8, 1162.	4.1	26
69	Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respiratory Research, 2019, 20, 30.	3.6	26
70	High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. European Respiratory Journal, 2020, 55, 1901314.	6.7	26
71	Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies. Respiratory Research, 2016, 17, 81.	3.6	25
72	>Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. International Journal of COPD, 2019, Volume 14, 1423-1439.	2.3	24

#	Article	IF	CITATIONS
73	Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction. Respiratory Research, 2015, 16, 85.	3.6	23
74	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	11.9	23
75	Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. European Respiratory Journal, 2015, 45, 1273-1282.	6.7	22
76	Effect of tiotropium on COPD exacerbations: A systematic review. Respiratory Medicine, 2016, 114, 1-8.	2.9	22
77	Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. Respiratory Research, 2018, 19, 11.	3.6	22
78	Constitutive immune activity promotes JNK- and FoxO-dependent remodeling of Drosophila airways. Cell Reports, 2021, 35, 108956.	6.4	22
79	Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany. Respiratory Research, 2021, 22, 108.	3.6	22
80	Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Research, 2019, 5, 00106-2019.	2.6	21
81	Burden of Pertussis in COPD: A Retrospective Database Study in England. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 157-169.	1.6	21
82	lgE is associated with exacerbations and lung function decline in COPD. Respiratory Research, 2022, 23, 1.	3.6	21
83	Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naÃ ⁻ ve patients. Respiratory Medicine, 2013, 107, 75-83.	2.9	20
84	Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure. Respiratory Medicine, 2015, 109, 1131-1137.	2.9	20
85	<p>Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population</p> . International Journal of COPD, 2019, Volume 14, 853-861.	2.3	20
86	Update in Chronic Obstructive Pulmonary Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 348-355.	5.6	20
87	Treatment response in COPD: does FEV ₁ say it all? A <i>post hoc</i> analysis of the CRYSTAL study. ERJ Open Research, 2019, 5, 00243-2018.	2.6	18
88	Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function. European Radiology, 2022, 32, 1879-1890.	4.5	18
89	Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 631-640.	5.6	18
90	Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation. Scientific Reports, 2020, 10, 241.	3.3	17

#	Article	IF	CITATIONS
91	Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis. International Journal of COPD, 2016, Volume 11, 3189-3197.	2.3	16
92	Pharmacological treatment of COPD: the devil is always in the detail. European Respiratory Journal, 2018, 51, 1800263.	6.7	16
93	CAT score single item analysis in patients with COPD: Results from COSYCONET. Respiratory Medicine, 2019, 159, 105810.	2.9	16
94	Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Research, 2020, 6, 00092-2020.	2.6	16
95	Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respiratory Research, 2017, 18, 14.	3.6	15
96	Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respiratory Research, 2017, 18, 60.	3.6	15
97	Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort. BMC Pulmonary Medicine, 2020, 20, 148.	2.0	15
98	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. International Journal of COPD, 2018, Volume 13, 1125-1134.	2.3	14
99	Pulmonary rehabilitation in long COVID: more than just natural recovery!?. ERJ Open Research, 2021, 7, 00454-2021.	2.6	14
100	COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. Respiratory Medicine, 2021, 185, 106461.	2.9	14
101	The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. Respiratory Research, 2019, 20, 257.	3.6	13
102	Exacerbations of chronic obstructive pulmonary disease: time to rename. Lancet Respiratory Medicine,the, 2020, 8, 133-135.	10.7	13
103	<p>Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort</p> . International Journal of COPD, 2020, Volume 15, 2787-2798.	2.3	13
104	Treating the Systemic Effects of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2011, 8, 376-379.	3.5	12
105	COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany. International Journal of COPD, 2021, Volume 16, 2407-2417.	2.3	12
106	Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans. Chronic Respiratory Disease, 2019, 16, 147997231877542.	2.4	11
107	Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. Respiratory Research, 2019, 20, 61.	3.6	11
108	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	3.2	11

#	Article	IF	CITATIONS
109	Time-updated resting heart rate predicts mortality in patients with COPD. Clinical Research in Cardiology, 2020, 109, 776-786.	3.3	11
110	Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort. Respiratory Medicine, 2020, 171, 106087.	2.9	11
111	COPD & amp; COVID-19. Archivos De Bronconeumologia, 2021, 57, 162-164.	0.8	11
112	Safety of biweekly α ₁ -antitrypsin treatment in the RAPID programme. European Respiratory Journal, 2018, 52, 1800897.	6.7	10
113	Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA. International Journal of COPD, 2018, Volume 13, 1455-1468.	2.3	10
114	<p>Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort</p> . Patient Preference and Adherence, 2019, Volume 13, 1711-1721.	1.8	10
115	Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials. Advances in Therapy, 2020, 37, 4266-4279.	2.9	10
116	Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease. Kidney International, 2021, 100, 1081-1091.	5.2	10
117	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Advances in Therapy, 2022, 39, 3957-3978.	2.9	10
118	From Heart Failure to Highly Unsaturated Fatty Acid Deficiency and Vice Versa: Bidirectional Heart and Liver Interactions. Canadian Journal of Cardiology, 2016, 32, 217-225.	1.7	9
119	Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences. International Journal of COPD, 2021, Volume 16, 987-998.	2.3	9
120	Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. Clinical Research in Cardiology, 2023, 112, 177-186.	3.3	9
121	COPD assessment: I, II, III, IV and/or A, B, C, D. European Respiratory Journal, 2014, 43, 949-950.	6.7	8
122	Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement. International Journal of COPD, 2021, Volume 16, 1215-1226.	2.3	8
123	Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET. ERJ Open Research, 2021, 7, 00242-2021.	2.6	8
124	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 2021, 58, 2102168.	6.7	8
125	Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. Scientific Reports, 2022, 12, 1435.	3.3	8
126	Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency & amp;ndash; analysis from the German Registry. International Journal of COPD, 2017, Volume 12, 1427-1437.	2.3	7

#	Article	IF	CITATIONS
127	Impact of baseline COPD symptom severity on the benefit from dual <i>versus</i> mono-bronchodilators: an analysis of the EMAX randomised controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096850.	2.6	7
128	Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data. International Journal of COPD, 2021, Volume 16, 2637-2651.	2.3	7
129	Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET. Respiratory Research, 2021, 22, 242.	3.6	7
130	COVID-19 and COPD: lessons beyond the pandemic. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L978-L982.	2.9	7
131	Implementation and use of mHealth home telemonitoring in adults with acute COVID-19 infection: a scoping review protocol. BMJ Open, 2021, 11, e053819.	1.9	7
132	Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ. Respiratory Medicine, 2017, 130, 1-8.	2.9	6
133	COPD & amp; COVID-19. Archivos De Bronconeumologia, 2021, 57, 162-164.	0.8	6
134	Echo <scp>Timeâ€Dependent</scp> Observed Lung <scp>T₁</scp> in Patients With Chronic Obstructive Pulmonary Disease in Correlation With Quantitative Imaging and Clinical Indices. Journal of Magnetic Resonance Imaging, 2021, 54, 1562-1571.	3.4	6
135	Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-NaÃ ⁻ ve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International Journal of COPD, 2021, Volume 16, 1939-1956.	2.3	6
136	Deterioration and Mortality Risk of COPD Patients Not Fitting into Standard GOLD Categories: Results of the COSYCONET Cohort. Respiration, 2021, 100, 308-317.	2.6	5
137	Transcriptional analysis identifies potential biomarkers and molecular regulators in acute malaria infection. Life Sciences, 2021, 270, 119158.	4.3	5
138	Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. International Journal of COPD, 2021, Volume 16, 3189-3199.	2.3	5
139	A scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic. Paediatric Respiratory Reviews, 2022, 43, 67-77.	1.8	5
140	Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. Respiration, 2022, 101, 307-320.	2.6	5
141	Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone. International Journal of COPD, 2022, Volume 17, 355-370.	2.3	5
142	Gardening can induce pulmonary failure: Aspergillus ARDS in an immunocompetent patient, a case report. BMC Infectious Diseases, 2014, 14, 600.	2.9	4
143	Changes in GOLD: today and tomorrow. Lancet Respiratory Medicine,the, 2015, 3, 424-426.	10.7	4
144	Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. Respiratory Medicine, 2020, 172, 106117.	2.9	4

#	Article	IF	CITATIONS
145	Assessing Symptom Burden. Clinics in Chest Medicine, 2020, 41, 367-373.	2.1	4
146	Early and sustained symptom improvement with umeclidinium/vilanterol <i>versus</i> monotherapy in COPD: a <i>post hoc</i> analysis of the EMAX randomised controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092694.	2.6	4
147	Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy, 2021, 38, 4815-4835.	2.9	4
148	Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial. Respiratory Research, 2021, 22, 279.	3.6	4
149	COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. Respiratory Medicine, 2020, 173, 106175.	2.9	4
150	Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD â€real world' study. Respiratory Research, 2022, 23, 109.	3.6	4
151	<p>Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients</p> . International Journal of COPD, 2020, Volume 15, 1831-1838.	2.3	3
152	Late Gadolinium Enhancement in Sarcoidosis. Chest, 2015, 147, e118.	0.8	2
153	Myocardial homing of mesenchymal stem cells following intrapericardial application and amplification by inflammation — an experimental pilot study. Canadian Journal of Physiology and Pharmacology, 2017, 95, 1064-1066.	1.4	2
154	COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study. Lung, 2020, 198, 507-514.	3.3	2
155	Use of the Evaluating Respiratory Symptomsâ,,¢ in COPD as an Outcome Measure in Clinical Trials: A Rapid Systematic Review. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 551-571.	0.7	2
156	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD, 2021, Volume 16, 3105-3118.	2.3	2
157	Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study. International Journal of COPD, 2020, Volume 15, 2739-2750.	2.3	0
158	Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. Respiratory Medicine, 2022, , 106918.	2.9	0